![](https://investorshub.advfn.com/uicon/591374.png?cb=1485035485)
Wednesday, March 01, 2017 8:34:47 PM
Most important for me is that the psoriasis cream is close to market and the sublingual tablet is close to market. I was expecting psoriasis cream and other creams first.
Sublingual tablet is good because that is a licensing play and OWCP could license its tablet IP to numerous companies that want to start their own clinical trials. Money would be minimal at first I would imagine, but in a few years when all those other meds are FDA approved it will be a non-stop source of revenue. Very, very promising. Recall, pure biotech companies have higher PE ratios than pure pharmas because pharmas have limited exclusivity before generics enter the market. In our case, even the generics will have to license OWCP's IP when the time comes.
I like it. I see the company having a very sober and realistic view of the near term. Yes, they would love to get PTSD and multiple myeloma to clinical FDA trails eventually, but they first need to build up a revenue engine to pay for those very, very costly moves.
Very exciting time to be an OWCP shareholder IMHO.
Know What You Own. My posts should not be construed as investment advice.
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM